Drug · CHEMBL384467
Comparisons in its trials740
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 740
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29) | 4,378 of 4,609 | 258 of 362 | 4,971 | NCT00103285 | Trial comparisons |
| Rolapitant + Granisetron + Dexamethasone vs Placebo + Granisetron + Dexamethasone: serious adverse events | 89 of 670 | 103 of 674 | 1,344 | NCT01500226 | Trial comparisons |
| Arm A Part 1 vs Arm B Part 1: Post-Consolidation Stringent Complete Response (sCR) Rate | 110 of 542 | 157 of 543 | 1,085 | NCT02541383 | Trial comparisons |
| Rescue Course of Betamethasone or Dexamethasone vs Placebo (Normal Saline): serious adverse events | 40 of 512 | 41 of 502 | 1,014 | NCT00201643 | Trial comparisons |
| Remdesivir Plus Baricitinib vs Remdesivir Plus Dexamethasone: deaths from any cause | 28 of 516 | 34 of 494 | 1,010 | NCT04640168 | Trial comparisons |
| Fosaprepitant Regimen vs Control Regimen: serious adverse events | 39 of 504 | 35 of 497 | 1,001 | NCT01594749 | Trial comparisons |
| Remdesivir Plus Baricitinib vs Remdesivir Plus Dexamethasone: serious adverse events | 95 of 503 | 94 of 482 | 985 | NCT04640168 | Trial comparisons |
| Bortezomib vs Carfilzomib: serious adverse events | 182 of 456 | 272 of 463 | 919 | NCT01568866 | Trial comparisons |
| APF530 + Fosaprepitant + Dexamethasone vs Ondansetron + Fosaprepitant + Dexamethasone: serious adverse events | 42 of 456 | 28 of 459 | 915 | NCT02106494 | Trial comparisons |
| Levofloxacin + Dexamethasone Followed by Dexamethasone vs Tobramycin + Dexamethasone: deaths from any cause | 1 of 395 | 0 of 393 | 788 | NCT03739528 | Trial comparisons |
| Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd): serious adverse events | 221 of 389 | 256 of 392 | 781 | NCT01080391 | Trial comparisons |
| Levofloxacin + Dexamethasone Followed by Dexamethasone vs Tobramycin + Dexamethasone: serious adverse events | 4 of 388 | 2 of 388 | 776 | NCT03739528 | Trial comparisons |
| PAN+BTZ vs PBO+BTZ: serious adverse events | 228 of 381 | 157 of 377 | 758 | NCT01023308 | Trial comparisons |
| E-Ld Cohort vs Ld Cohort: deaths from any cause | 240 of 374 | 232 of 374 | 748 | NCT01335399 | Trial comparisons |
| E-Ld Cohort vs Ld Cohort: serious adverse events | 293 of 371 | 279 of 371 | 742 | NCT01335399 | Trial comparisons |
| Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd): deaths from any cause | 259 of 369 | 287 of 368 | 737 | NCT02252172 | Trial comparisons |
| Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd): serious adverse events | 262 of 365 | 289 of 364 | 729 | NCT02252172 | Trial comparisons |
| Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Progression Free Survival (PFS) | 103 of 354 | 50 of 355 | 709 | NCT03710603 | Trial comparisons |
| Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): deaths from any cause | 44 of 354 | 34 of 355 | 709 | NCT03710603 | Trial comparisons |
| Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Overall MRD Negativity Rate | 168 of 354 | 267 of 355 | 709 | NCT03710603 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL384467/comparisons